PATHWAY Clinical Research Study for EPP & XLP
The PATHWAY clinical research study is evaluating an investigational medication called PORT-77 for people living with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP).
The PATHWAY clinical research study is evaluating an investigational medication called PORT-77 for people living with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP).